Literature DB >> 22326117

[Radiobiology dedicated to endothelium].

S Supiot1, F Paris.   

Abstract

Radiotherapy is used in more than 60% of the curative or palliative intent treatment against cancer. However, its effectiveness is often limited by intrinsic resistance of cancer cells and the radiation toxicity of the surrounding normal tissue. New paradigms in oncology are not only focused on tumor cells, but also considered non-transformed from the stromal cells as potential therapeutic target. Among the different cell types, endothelial cells play a singular role, due by their presence, in the vast majority of tumors but also of healthy tissue. This review proposes to participate in the understanding of the response of the endothelium, in the radiation sensitivity of tumor and healthy tissue after radiotherapy.
Copyright © 2012. Published by Elsevier SAS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22326117     DOI: 10.1016/j.canrad.2011.10.006

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  3 in total

1.  Improved functionality of the vasculature during conventionally fractionated radiation therapy of prostate cancer.

Authors:  Vincent A Potiron; Rym Abderrahmani; Karen Clément-Colmou; Séverine Marionneau-Lambot; Thibauld Oullier; François Paris; Stéphane Supiot
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

Review 2.  Membrane signaling induced by high doses of ionizing radiation in the endothelial compartment. Relevance in radiation toxicity.

Authors:  Isabelle Corre; Maëva Guillonneau; François Paris
Journal:  Int J Mol Sci       Date:  2013-11-18       Impact factor: 5.923

3.  Endothelial Hey2 deletion reduces endothelial-to-mesenchymal transition and mitigates radiation proctitis in mice.

Authors:  Elodie Mintet; Jérémy Lavigne; Vincent Paget; Georges Tarlet; Valérie Buard; Olivier Guipaud; Jean-Christophe Sabourin; Maria-Luisa Iruela-Arispe; Fabien Milliat; Agnès François
Journal:  Sci Rep       Date:  2017-07-10       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.